BACKGROUND AND OBJECTIVE: Lipid therapeutic goals are not achieved in a high percentage of @entity1 with @entity453 ( @entity453 ). We describe in this paper the methodology and results of the Hospital Universitario de Bellvitge @entity731 Secondary Preventive Program (PPSHB), which is aimed at preventing @entity63 recurrences by controlling atherogenic factors. @entity1 AND METHOD: From January 1992 to December 1996, 882 @entity1 with acute @entity453 entered the PPSHB and were seen on at least 2 occasions at the Unidad de L  pidos y @entity4288 during a mean period of 10.4 (3.8) months. In 753 @entity1 data on clinical follow-up were available. Follow-up data were collected by telephone interview and review of medical records. RESULTS: During the follow-up period at the Unidad de L  pidos y @entity4288 , 71.9% of @entity1 achieved the therapeutic goals or their LDLc improved >= 15%. These results were seen in 83.6%, 78.7% and 83.6% of @entity1 with regard to HDLc, @entity1674 and HDLc/LDLc ratio, respectively, while the percentage of @entity1 receiving lipid-lowering drugs increased from 28% to 69%. During a follow-up of 33.7 (15.9) months, @entity204 (all causes; mean survival time: 20 [13.4] months) occurred in 41 @entity1 (5.4%). On the other hand, hospitalization for @entity65 was required in 113 @entity1 (15%) during a mean follow-up until the first admission of 18.4 (14.2) months. The main independent predictor of unfavourable clinical course was not to reach the HDLc/LDLc ratio goal (HDLc/LDLc >= 0.27 or an increase >= 15%; OR = 2.1; 95% CI, 1.1-4.03). CONCLUSIONS: A systematic secondary preventive strategy may help achieve an adequate control of @entity2299 in most @entity453 @entity1 . In these @entity1 , achieving the HDLc/LDLc therapeutic goal is associated with a less than half risk of hospitalization for @entity65 or @entity204 from any cause.

[Secondary Preventive Program of XXXX in a university hospital. Results and predictors of clinical course].

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity731 :: ('MESH:D050197', 'Disease') :: ['Atherosclerosis'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides'] @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity4288 :: ('MESH:D001161', 'Disease') :: ['Arteriosclerosis']
@entity731 :: (MESH:D050197,Disease) :: ['atherosclerosis']
